Addison Advisors LLC Sells 1,389 Shares of CVS Health Co. (NYSE:CVS)

Addison Advisors LLC lessened its stake in shares of CVS Health Co. (NYSE:CVS) by 17.8% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 6,426 shares of the pharmacy operator’s stock after selling 1,389 shares during the period. Addison Advisors LLC’s holdings in CVS Health were worth $288,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. AMF Tjanstepension AB boosted its stake in shares of CVS Health by 124.1% in the third quarter. AMF Tjanstepension AB now owns 61,744 shares of the pharmacy operator’s stock worth $3,882,000 after acquiring an additional 34,198 shares during the period. Allworth Financial LP boosted its stake in shares of CVS Health by 10.7% in the third quarter. Allworth Financial LP now owns 17,613 shares of the pharmacy operator’s stock worth $1,108,000 after acquiring an additional 1,706 shares during the period. DekaBank Deutsche Girozentrale boosted its stake in shares of CVS Health by 222.9% in the third quarter. DekaBank Deutsche Girozentrale now owns 1,858,556 shares of the pharmacy operator’s stock worth $113,855,000 after acquiring an additional 1,282,956 shares during the period. Bristlecone Advisors LLC boosted its stake in shares of CVS Health by 4.0% in the third quarter. Bristlecone Advisors LLC now owns 10,340 shares of the pharmacy operator’s stock worth $650,000 after acquiring an additional 395 shares during the period. Finally, Insight Folios Inc boosted its stake in shares of CVS Health by 3.5% in the third quarter. Insight Folios Inc now owns 8,250 shares of the pharmacy operator’s stock worth $519,000 after acquiring an additional 282 shares during the period. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Down 0.8 %

Shares of NYSE:CVS opened at $62.95 on Tuesday. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $80.75. The stock has a market cap of $79.37 billion, a P/E ratio of 17.20, a price-to-earnings-growth ratio of 0.98 and a beta of 0.61. The business’s 50 day moving average is $52.72 and its 200 day moving average is $56.25. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Sell-side analysts predict that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were given a dividend of $0.665 per share. The ex-dividend date was Thursday, January 23rd. This represents a $2.66 annualized dividend and a yield of 4.23%. CVS Health’s dividend payout ratio (DPR) is presently 72.68%.

Analyst Ratings Changes

CVS has been the subject of a number of recent analyst reports. Edward Jones raised CVS Health from a “hold” rating to a “buy” rating in a research note on Thursday, January 30th. JPMorgan Chase & Co. upped their price objective on CVS Health from $80.00 to $81.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 18th. Wells Fargo & Company boosted their target price on CVS Health from $68.00 to $73.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Piper Sandler decreased their target price on CVS Health from $72.00 to $64.00 and set an “overweight” rating on the stock in a research report on Monday, November 25th. Finally, Barclays boosted their target price on CVS Health from $71.00 to $73.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $70.00.

Insider Buying and Selling at CVS Health

In related news, Director Michael F. Mahoney bought 30,000 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were acquired at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the transaction, the director now owns 39,356 shares of the company’s stock, valued at $2,625,045.20. The trade was a 320.65 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.24% of the company’s stock.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.